Trevi Therapeutics, INC. (TRVI) — SEC Filings

Overview

Trevi Therapeutics, INC. (TRVI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 17, 2026: Trevi Therapeutics, Inc. filed an 8-K on April 17, 2026, reporting on a material definitive agreement, results of operations, and other events. The filing includes various exhibits such as financial statements and legal opinions, indicating significant corporate activity. The company is involved in

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Trevi Therapeutics, INC. is neutral.

Filing Type Overview

Trevi Therapeutics, INC. (TRVI) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13D/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• Trevi Therapeutics Files 8-K with Material Agreements — 8-K · Apr 17, 2026 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on April 17, 2026, reporting on a material definitive agreement, results of operations, and other events. The filing inclu
• 8-K Filing — 8-K · Dec 5, 2025
• Trevi Narrows Q3 Loss Amid Haduvio Development, Boosts Cash Reserves — 10-Q · Nov 13, 2025 Risk: high
  Trevi Therapeutics, Inc. (TRVI) reported a net loss of $11.802 million for the three months ended September 30, 2025, an improvement from the $13.242 million ne
• Trevi Therapeutics Reports Officer and Director Changes — 8-K · Aug 20, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting events as of August 14, 2025. The filing indicates changes related to the departure of direc
• Trevi Therapeutics Widens Q2 Loss Amid Rising G&A Costs — 10-Q · Aug 7, 2025 Risk: high
  Trevi Therapeutics, Inc. reported a net loss of $14.5 million for the three months ended June 30, 2025, compared to a net loss of $13.2 million for the same per
• Trevi Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 17, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting events that occurred on June 11, 2025. The filing indicates changes related to the departure o
• Trevi Therapeutics Files 8-K: Material Agreement, Other Events — 8-K · Jun 4, 2025 Risk: medium
  On June 3, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial sta
• Trevi Therapeutics Files 8-K for Other Events — 8-K · Jun 2, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events,
• Trevi Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations. Key fin
• Trevi Therapeutics Files DEF 14A on Executive Compensation — DEF 14A · Apr 29, 2025 Risk: low
  Trevi Therapeutics, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2023,
• Trevi Therapeutics Files 2024 10-K — 10-K · Mar 18, 2025 Risk: low
  Trevi Therapeutics, Inc. filed its 2024 10-K on March 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical pr
• Trevi Therapeutics Files 8-K Report — 8-K · Mar 10, 2025 Risk: low
  On March 10, 2025, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial tr
• Trevi Therapeutics Files 8-K on Operations and Financials — 8-K · Jan 8, 2025 Risk: medium
  On January 8, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing significant corporate events. The filing indicates the company is providing updates o
• Trevi Therapeutics Files 8-K: Material Agreement & Other Events — 8-K · Dec 16, 2024 Risk: medium
  On December 15, 2024, Trevi Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhi
• Trevi Therapeutics Files 8-K Report — 8-K · Dec 12, 2024 Risk: low
  On December 12, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No spec
• Trevi Therapeutics Files 8-K Report — 8-K · Dec 3, 2024 Risk: low
  On December 3, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is no
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• NEA 16 Amends Trevi Therapeutics Stake Filing — SC 13D/A · Nov 8, 2024 Risk: medium
  New Enterprise Associates 16, L.P. (NEA 16) filed an amendment to its Schedule 13D on November 8, 2024, regarding its holdings in Trevi Therapeutics, Inc. The f
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• Trevi Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Trevi Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financia
• SC 13G/A Filing — SC 13G/A · Oct 23, 2024
• Trevi Therapeutics Files 8-K Report — 8-K · Oct 21, 2024 Risk: low
  On October 21, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial
• Trevi Therapeutics Files 8-K — 8-K · Oct 4, 2024 Risk: low
  Trevi Therapeutics, Inc. filed an 8-K on October 4, 2024, reporting an event that occurred on October 3, 2024. The filing is categorized under 'Other Events' an
• Trevi Therapeutics Files 8-K on Director and Officer Changes — 8-K · Oct 1, 2024 Risk: low
  On September 27, 2024, Trevi Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fil
• Trevi Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Trevi Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second qua
• SC 13G/A Filing — SC 13G/A · Jul 11, 2024
• Trevi Therapeutics Files 8-K: Shareholder Vote & Financials — 8-K · Jun 13, 2024 Risk: medium
  On June 13, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders an
• NEA 16 Group Amends Trevi Therapeutics Stake to 5.8% — SC 13D/A · May 21, 2024 Risk: medium
  New Enterprise Associates 16, L.P. (NEA 16) and its affiliates have amended their Schedule 13D filing for Trevi Therapeutics, Inc. (TRVI) as of May 21, 2024. Th
• Trevi Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Trevi Therapeutics, Inc. (TRVI) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Trevi Therapeutics, Inc. filed a 10-Q report for the period ending
• Trevi Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13 — DEF 14A · Apr 26, 2024 Risk: low
  Trevi Therapeutics, Inc. (TRVI) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting to be held virtually on June 13, 2024, at 12:30
• SC 13G/A Filing — SC 13G/A · Apr 25, 2024
• Trevi Therapeutics Files 2023 10-K — 10-K · Mar 20, 2024 Risk: medium
  Trevi Therapeutics, Inc. filed its 2023 10-K on March 20, 2024, reporting on its fiscal year ending December 31, 2023. The company, operating in pharmaceutical
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Rubric Capital Discloses 5.68M Shares in Trevi Therapeutics — SC 13G/A · Feb 12, 2024 Risk: low
  Rubric Capital Management LP, an investment firm based in New York, filed an amended SC 13G/A on February 12, 2024, disclosing its ownership in Trevi Therapeuti

Frequently Asked Questions